We are live on ! Find out more
CRSP icon

CRISPR Therapeutics

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 92 funds opening new positions, 128 increasing their positions, 103 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more capital inflows, than outflows

Capital inflows: $567M | Capital outflows: $262M

53% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 60

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

24% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 103

9% more funds holding

Funds holding: 398 → 433 (+35)

8.39% more ownership

Funds ownership: 75.35% → 83.74% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+35
Holders Change %
+8.79%
% of All Funds
5.67%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
92
Increased
128
Reduced
103
Closed
60
Calls
$244​M
Puts
$186​M
Net Calls
+$58.2​M
Net Calls Change
+$37.5​M

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new CRSP positions and 60 closed out — a net gain of 32 holders — while 128 added to existing stakes and 103 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 398 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 92 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +32 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.